Stockscreener 앱 받기
16.28
0.60%
0.3285
전일 마감가:
$16.61
열려 있는:
$16.72
하루 거래량:
20,630
Relative Volume:
0.04
시가총액:
$713.91M
수익:
$9.00M
순이익/손실:
$-80.61M
주가수익비율:
-7.2582
EPS:
-2.2432
순현금흐름:
$-82.35M
1주 성능:
+2.08%
1개월 성능:
-1.99%
6개월 성능:
+78.72%
1년 성능:
+311.58%
1일 변동 폭
$16.01
$16.73
1주일 범위
$15.56
$17.33
52주 변동 폭
$3.79
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.06 | 738.36M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
15.98 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.315 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.23 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.97 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
567.07 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Needham | Buy |
| 2026-02-25 | 개시 | Oppenheimer | Outperform |
| 2026-02-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-01-27 | 개시 | Piper Sandler | Overweight |
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, vs. FactSet Est of $1.1M - marketscreener.com
BioAge Labs (NASDAQ: BIOA) Q1 2026 loss deepens amid R&D and pipeline push - Stock Titan
[10-Q] BioAge Labs, Inc. Quarterly Earnings Report - Stock Titan
BioAge lines up 2 mid-2026 trials for once-daily pill after $132M raise - Stock Titan
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, Vs. FactSet Est of $1.1M - Moomoo
Press Release: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
BioAge to preview early data for heart and retinal disease drug - Stock Titan
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - The Manila Times
PRN_FinancialWrapper | PR NewswireBioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - FinancialContent
BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake - Stock Titan
BioAge Labs (NASDAQ:BIOA) Trading 8.6% HigherHere's Why - MarketBeat
BioAge Labs plans up to $75M public stock offering; shares down - MSN
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell - MarketBeat
BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares - Stock Titan
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - MarketBeat
BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class ActionBIOA - TMX Newsfile
BIOA SEC FilingsBioAge Labs Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1%Time to Sell? - MarketBeat
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Sahm
BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm. - Xã Vĩnh Công
[ARS] BioAge Labs, Inc. SEC Filing - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com South Africa
Bioage Labs Inc (BIOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bioage Labs Inc 주식 (BIOA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
5.05 |
8,820 |
44,572 |
8,820 |
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Sale |
17.81 |
8,820 |
157,084 |
0 |
1.38%
1.89%
자본화:
|
볼륨(24시간):